Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hemogenyx Pharmaceuticals Plc. (OP: HOPHF )

0.0031 UNCHANGED
Last Price Updated: 12:21 PM EDT, Aug 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Hemogenyx Pharmaceuticals Plc.

< Previous 1 2 Next >
Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Half-year Report
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC - FLT3 Assay Ready for Phase I Trials at MD Anderson
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CDX Development Update
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Presentation at CBD S&T Conference
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Macrophage-Directed Therapies Summit Presentation
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Operations Update
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Brain Delivery
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Intranasal Delivery
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Final Results
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights
Via ACCESSWIRE
Hemogenyx Pharmaceuticals discusses successful £3.5M capital raise as it advances HEMO-CAR-T program
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) Dr Vladislav Sandler joins Proactive's Stephen Gunnion after the pre-clinical stage biopharmaceutical group raised £3.5 million, which will be... 
Via TheNewswire.com
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise US$4.2 million
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces the Approval and Issuance of U.S. Conditioning Patent
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Submission of Complete Response to Clinical Hold
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of Cancer
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Lentivirus Re-manufacturing Completed
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T Process Qualification Run Completed
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £534,375
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC - Clinical Hold Lift Plan is accepted by FDA
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Patent Application Update
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Clinical Hold on IND for HEMO-CAR-T
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Equity Incentive Pool Increase and Option Grant
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Full FDA Review for HEMO-CAR-T IND
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Submission of IND for HEMO-CAR-T
Via ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Final Results for the Year Ended 31 December 2022
Via ACCESSWIRE
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.